From negotiations to legislation, Brexit continues to hang heavy over the political scene this February as Prime Minister Theresa May struggles for her political survival amid mutinous mutterings over the next phase talks.
The House of Lords will take centre stage in the battle over future regulation as it considers the European Union (Withdrawal) Bill at the Committee Stage.
Meanwhile, speculation will soon commence about the contents of the Chancellor's upcoming Spring Statement.
Here, Daniel Shaw-Stewart, DeHavilland's Monitoring Consultant for Health and Pharmaceuticals policy, gives you the lowdown on what to watch out for this February.
What's on the agenda this month
by Daniel Shaw-Stewart, Monitoring Consultant
A number of important reviews and initiatives have been launched in recent days which look set to occupy health professionals in the months ahead.
Firstly, the Care Quality Commission has published its plans on how to develop its next phase of regulation for independent healthcare services. Moreover, the Department of Health and Social Care has launched a landmark review into over-the-counter prescription drugs. These two new reviews are poised to change the shape of the health sector for the foreseeable future.
Additionally, following January’s Cabinet reshuffle, responsibility for the forthcoming Green Paper on care and support for older people has been transferred from the Cabinet Office to the DHSC. Care Minister Caroline Dinenage will be working closely with the Department for Work and Pensions and the new Minister for Loneliness Tracey Crouch at the Department for Digital, Culture, Media and Sport to shape the future regulatory landscape of social care.
Lastly, the European Union (Withdrawal) Bill is set to undergo a number of amendments as peers seek to radically modify the face of the Bill. A number of senior stakeholders have warned of the risks posed by Brexit to future patient access to the latest drugs. The Brexit Health Alliance has warned of a possible problems with NHS access to medicines unless the pharmaceuticals industry can ensure continued regulatory alignment between the UK and EU.
Get all the latest on the issues that matter from our dedicated Monitoring Consultants
DeHavilland's team of Monitoring Consultants offer you essential public affairs support to keep track of everything that matters.
Join us for a trial and you'll receive personalised support from Daniel and the team, including alerts, roundups and acess to original research services.
Daniel serves as Monitoring Consultant for DeHavilland's UK Health clients. He has previously worked at MHP Communications in its Corporate Affairs Team, and at the BBC during the 2015 General Election as a Production Assistant. He read History and Politics at Goldsmiths, University of London.